FDA 批准阿达木单抗生物仿制药用于患有葡萄膜炎的 2+ 儿童和患有汗腺炎的 12+ 青少年。 FDA approves adalimumab biosimilar for kids 2+ with uveitis and teens 12+ with hidradenitis.

美国食品和药物管理局批准了扩大阿达利姆巴-阿提 (Yuflyma及其非品牌版本) 的儿科用途,允许对12岁及以上的患有状腺炎的青少年和患有脑膜炎的2岁儿童进行治疗. The FDA has approved expanded pediatric uses for adalimumab-aaty (Yuflyma and its unbranded version), allowing treatment for adolescents aged 12 and older with hidradenitis suppurativa and children as young as 2 with uveitis. 已经获准用于其他免疫媒介疾病的类似生物现在可以与Humira互换,意思是可以取代,而没有临床风险。 The biosimilar, already approved for other immune-mediated diseases, is now interchangeable with Humira, meaning it can be substituted without clinical risk. 在预先填充的注射器和自动注射器中,它为患有慢性炎症的年轻病人提供了更广泛的负担得起的治疗机会,这可能对健康和生活质量造成严重的影响。 Available in prefilled syringes and autoinjectors, it offers broader access to affordable treatment for younger patients with chronic inflammatory conditions, which can cause serious health and quality-of-life impacts.